CN101132812A - Hiv进入抑制剂的聚合物基组合物和结合物 - Google Patents

Hiv进入抑制剂的聚合物基组合物和结合物 Download PDF

Info

Publication number
CN101132812A
CN101132812A CNA2005800082104A CN200580008210A CN101132812A CN 101132812 A CN101132812 A CN 101132812A CN A2005800082104 A CNA2005800082104 A CN A2005800082104A CN 200580008210 A CN200580008210 A CN 200580008210A CN 101132812 A CN101132812 A CN 101132812A
Authority
CN
China
Prior art keywords
conjugate
polymer
peg
hydrogel
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800082104A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·D·本特利
赵宣
哈罗德·察佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics AL Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics AL Corp filed Critical Nektar Therapeutics AL Corp
Publication of CN101132812A publication Critical patent/CN101132812A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/46—Polyesters chemically modified by esterification
    • C08G63/48—Polyesters chemically modified by esterification by unsaturated higher fatty oils or their acids; by resin acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2005800082104A 2004-03-15 2005-03-15 Hiv进入抑制剂的聚合物基组合物和结合物 Pending CN101132812A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55314604P 2004-03-15 2004-03-15
US60/553,146 2004-03-15

Publications (1)

Publication Number Publication Date
CN101132812A true CN101132812A (zh) 2008-02-27

Family

ID=34994420

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800082104A Pending CN101132812A (zh) 2004-03-15 2005-03-15 Hiv进入抑制剂的聚合物基组合物和结合物

Country Status (9)

Country Link
US (1) US9446139B2 (https=)
EP (1) EP1725262B1 (https=)
JP (1) JP4805911B2 (https=)
KR (1) KR101276422B1 (https=)
CN (1) CN101132812A (https=)
AU (1) AU2005222641B2 (https=)
CA (1) CA2558583C (https=)
MX (1) MXPA06010505A (https=)
WO (1) WO2005089805A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104109240A (zh) * 2014-07-13 2014-10-22 成都市绿科华通科技有限公司 一种可作为药物载体的多孔聚乙二醇的制备方法
CN104303058A (zh) * 2012-04-18 2015-01-21 西门子医疗保健诊断公司 用于制备缀合物试剂的化合物和方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007151A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
US7432331B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
AU2004313242A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
DE102004031258A1 (de) * 2004-06-29 2006-02-09 Jennissen, Herbert P., Prof. Dr. Proteinhybride mit polyhydroxyaromatischen Aminosäure-Epitopen
WO2006110776A2 (en) 2005-04-12 2006-10-19 Nektar Therapeutics Al, Corporation Polyethylene glycol cojugates of antimicrobial agents
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US8309680B2 (en) 2006-02-21 2012-11-13 Nektar Therapeutics Segmented degradable polymers and conjugates made therefrom
EP2089052A4 (en) * 2006-05-24 2011-02-16 Peg Biosciences POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS
PL2054074T3 (pl) 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
EP2134181A4 (en) * 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
CA2682848A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
KR20110075029A (ko) * 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
PT2501413T (pt) * 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
WO2011084458A2 (en) * 2009-12-15 2011-07-14 The Johns Hopkins University Polymer-based compositions and methods for treatment of peritoneal disorders
US20110293686A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3670276B2 (ja) 1991-02-08 2005-07-13 プロゲニクス・ファーマスーティカルズ、インコーポレイテッド ＣＤ４― ガンマ・２キメラ及びＣＤ４ ― ＩｇＧ２・キメラ
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
JP4078032B2 (ja) * 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6469136B1 (en) 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6602498B2 (en) * 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001247254A1 (en) 2000-02-29 2001-09-12 Aaron Diamond Aids Research Centre Sulfated CCR5 peptides for HIV -1 infection
MXPA05000796A (es) 2002-07-24 2005-04-19 Hoffmann La Roche Aditivos de acidos polialquilenglicolicos.
HRP20050024A2 (en) 2002-07-24 2006-02-28 F. Hoffmann - La Roche Ag Pegylated t20 polypeptide
WO2004013165A1 (en) 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Pegylated t1249 polypeptide
KR20050093856A (ko) * 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
DE60331860D1 (en) * 2002-12-30 2010-05-06 Nektar Therapeutics Mehrarmige polypeptid-poly(ethylenglykol)-blockcopolymere als arzneistoffzufuhrvehikel
DE60322111D1 (de) * 2002-12-31 2008-08-21 Nektar Therapeutics Al Co Verfahren zur herstellung von hydrogelen aus thiosulfonat-zusammensetzungen und ihre verwendungen
JP4490369B2 (ja) * 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
KR101207247B1 (ko) 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
EP2644206B1 (en) * 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
CA2556032A1 (en) * 2004-03-15 2005-09-29 Trimeris, Inc. Site-specific chemical modification of hiv gp41-derived peptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104303058A (zh) * 2012-04-18 2015-01-21 西门子医疗保健诊断公司 用于制备缀合物试剂的化合物和方法
CN104109240A (zh) * 2014-07-13 2014-10-22 成都市绿科华通科技有限公司 一种可作为药物载体的多孔聚乙二醇的制备方法

Also Published As

Publication number Publication date
EP1725262A2 (en) 2006-11-29
US20050226843A1 (en) 2005-10-13
CA2558583A1 (en) 2005-09-29
US9446139B2 (en) 2016-09-20
MXPA06010505A (es) 2006-12-19
CA2558583C (en) 2013-07-09
WO2005089805A3 (en) 2007-07-19
JP4805911B2 (ja) 2011-11-02
JP2007529539A (ja) 2007-10-25
KR20060130225A (ko) 2006-12-18
WO2005089805A2 (en) 2005-09-29
KR101276422B1 (ko) 2013-06-19
AU2005222641B2 (en) 2011-04-07
EP1725262B1 (en) 2021-05-26
AU2005222641A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
JP4805911B2 (ja) Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
EP1885403B1 (en) Poly(ethyleneglycol) conjugates of Lysostaphin
JP6728055B2 (ja) Ｉｌ−１５部分とポリマーとのコンジュゲート
JP5431874B2 (ja) ポリエチレングリコール−ｇｒｆ結合体の部位特異的調製方法
CA2978330C (en) Conjugates of an il-7 moiety and a polymer
CN104906594B (zh) 用于与蛋白质和肽缀合的四个支链的树枝状大分子peg
CN1997661A (zh) 抗原性减弱的聚合物缀合物,其制备方法和应用
WO2013020079A2 (en) Conjugates of an il-11 moiety and a polymer
CA2648582C (en) Conjugates of an anti-tnf-alpha antibody
AU2009246851A1 (en) Conjugates of a cholinesterase moiety and a polymer
Belcheva et al. Synthesis and characterization of polymer-(multi)-peptide conjugates for control of specific cell aggregation
US20230272001A1 (en) Novel processes for preparing conjugates of the il-2 protein
JP7618383B2 (ja) オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: ALABAMA STATE,USA TO: CALIFORNIA STATE, U.S.A.

TA01 Transfer of patent application right

Effective date of registration: 20100407

Address after: American California

Applicant after: Nektar Therapeutics

Address before: alabama

Applicant before: Nektar Therapeutics Al Corp.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080227